Literature DB >> 28822967

Temporal dynamics of cardiac hypertrophic growth in response to pressure overload.

Yuan Wang1,2, Yuannyu Zhang3, Guanqiao Ding1, Herman I May1, Jian Xu3, Thomas G Gillette1, Hang Wang2, Zhao V Wang4.   

Abstract

Hypertension is one of the most important risk factors of heart failure. In response to high blood pressure, the left ventricle manifests hypertrophic growth to ameliorate wall stress, which may progress into decompensation and trigger pathological cardiac remodeling. Despite the clinical importance, the temporal dynamics of pathological cardiac growth remain elusive. Here, we took advantage of the puromycin labeling approach to measure the relative rates of protein synthesis as a way to delineate the temporal regulation of cardiac hypertrophic growth. We first identified the optimal treatment conditions for puromycin in neonatal rat ventricular myocyte culture. We went on to demonstrate that myocyte growth reached its peak rate after 8-10 h of growth stimulation. At the in vivo level, with the use of an acute surgical model of pressure-overload stress, we observed the maximal growth rate to occur at day 7 after surgery. Moreover, RNA sequencing analysis supports that the most profound transcriptomic changes occur during the early phase of hypertrophic growth. Our results therefore suggest that cardiac myocytes mount an immediate growth response in reply to pressure overload followed by a gradual return to basal levels of protein synthesis, highlighting the temporal dynamics of pathological cardiac hypertrophic growth.NEW & NOTEWORTHY We determined the optimal conditions of puromycin incorporation in cardiac myocyte culture. We took advantage of this approach to identify the growth dynamics of cardiac myocytes in vitro. We went further to discover the protein synthesis rate in vivo, which provides novel insights about cardiac temporal growth dynamics in response to pressure overload.
Copyright © 2017 the American Physiological Society.

Entities:  

Keywords:  cardiac myocyte; growth dynamics; pathological cardiac hypertrophy; pressure overload; puromycin

Mesh:

Substances:

Year:  2017        PMID: 28822967      PMCID: PMC6148204          DOI: 10.1152/ajpheart.00284.2017

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  37 in total

1.  Dual roles of modulatory calcineurin-interacting protein 1 in cardiac hypertrophy.

Authors:  Rick B Vega; Beverly A Rothermel; Carla J Weinheimer; Atilla Kovacs; R H Naseem; Rhonda Bassel-Duby; R S Williams; Eric N Olson
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-06       Impact factor: 11.205

Review 2.  Endoplasmic reticulum stress in the heart.

Authors:  Christopher C Glembotski
Journal:  Circ Res       Date:  2007-11-09       Impact factor: 17.367

Review 3.  The failing heart--an engine out of fuel.

Authors:  Stefan Neubauer
Journal:  N Engl J Med       Date:  2007-03-15       Impact factor: 91.245

Review 4.  Cardiac plasticity.

Authors:  Joseph A Hill; Eric N Olson
Journal:  N Engl J Med       Date:  2008-03-27       Impact factor: 91.245

5.  Hypertension among adults in the United States: National Health and Nutrition Examination Survey, 2011-2012.

Authors:  Tatiana Nwankwo; Sung Sug Yoon; Vicki Burt; Quiping Gu
Journal:  NCHS Data Brief       Date:  2013-10

Review 6.  The progression of hypertensive heart disease.

Authors:  Mark H Drazner
Journal:  Circulation       Date:  2011-01-25       Impact factor: 29.690

7.  Reversibility of adverse, calcineurin-dependent cardiac remodeling.

Authors:  Jeff M Berry; Vien Le; David Rotter; Pavan K Battiprolu; Bennett Grinsfelder; Paul Tannous; Jana S Burchfield; Michael Czubryt; Johannes Backs; Eric N Olson; Beverly A Rothermel; Joseph A Hill
Journal:  Circ Res       Date:  2011-06-23       Impact factor: 17.367

8.  Differential activation of stress-response signaling in load-induced cardiac hypertrophy and failure.

Authors:  Beverly A Rothermel; Kambeez Berenji; Paul Tannous; William Kutschke; Asim Dey; Bridgid Nolan; Ki-Dong Yoo; Elaine Demetroulis; Michael Gimbel; Barry Cabuay; Mohsen Karimi; Joseph A Hill
Journal:  Physiol Genomics       Date:  2005-07-20       Impact factor: 3.107

Review 9.  Measuring protein synthesis with SUnSET: a valid alternative to traditional techniques?

Authors:  Craig A Goodman; Troy A Hornberger
Journal:  Exerc Sport Sci Rev       Date:  2013-04       Impact factor: 6.230

Review 10.  Antihypertensive effects of peroxisome proliferator-activated receptor-β/δ activation.

Authors:  Marta Toral; Miguel Romero; Francisco Pérez-Vizcaíno; Juan Duarte; Rosario Jiménez
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-11-23       Impact factor: 5.125

View more
  9 in total

1.  Spliced X-box Binding Protein 1 Stimulates Adaptive Growth Through Activation of mTOR.

Authors:  Xiaoding Wang; Yingfeng Deng; Guangyu Zhang; Chao Li; Guanqiao Ding; Herman I May; Diem H Tran; Xiang Luo; Ding-Sheng Jiang; Dan L Li; Xiang Wei; Lin Xu; Anwarul Ferdous; Thomas G Gillette; Philipp E Scherer; Xuejun Jiang; Zhao V Wang
Journal:  Circulation       Date:  2019-06-10       Impact factor: 29.690

2.  ATF6 Regulates Cardiac Hypertrophy by Transcriptional Induction of the mTORC1 Activator, Rheb.

Authors:  Erik A Blackwood; Christoph Hofmann; Michelle Santo Domingo; Alina S Bilal; Anup Sarakki; Winston Stauffer; Adrian Arrieta; Donna J Thuerauf; Fred W Kolkhorst; Oliver J Müller; Tobias Jakobi; Christoph Dieterich; Hugo A Katus; Shirin Doroudgar; Christopher C Glembotski
Journal:  Circ Res       Date:  2019-01-04       Impact factor: 17.367

3.  GRP78 (Glucose-Regulated Protein of 78 kDa) Promotes Cardiomyocyte Growth Through Activation of GATA4 (GATA-Binding Protein 4).

Authors:  Guangyu Zhang; Xiaoding Wang; Xukun Bi; Chao Li; Yingfeng Deng; Ali A Al-Hashimi; Xiang Luo; Thomas G Gillette; Richard C Austin; Yanggan Wang; Zhao V Wang
Journal:  Hypertension       Date:  2019-02       Impact factor: 10.190

4.  ATF4 Protects the Heart From Failure by Antagonizing Oxidative Stress.

Authors:  Xiaoding Wang; Guangyu Zhang; Subhajit Dasgupta; Erica L Niewold; Chao Li; Qinfeng Li; Xiang Luo; Lin Tan; Anwarul Ferdous; Philip L Lorenzi; Beverly A Rothermel; Thomas G Gillette; Christopher M Adams; Philipp E Scherer; Joseph A Hill; Zhao V Wang
Journal:  Circ Res       Date:  2022-05-16       Impact factor: 23.213

5.  Integrated Stress Response Couples Mitochondrial Protein Translation With Oxidative Stress Control.

Authors:  Guangyu Zhang; Xiaoding Wang; Chao Li; Qinfeng Li; Yu A An; Xiang Luo; Yingfeng Deng; Thomas G Gillette; Philipp E Scherer; Zhao V Wang
Journal:  Circulation       Date:  2021-09-29       Impact factor: 29.690

6.  iTRAQ‑based quantitative proteomics analysis of the potential application of secretoneurin gene therapy for cardiac hypertrophy induced by DL‑isoproterenol hydrochloride in mice.

Authors:  Huali Chen; Mingjun Wu; Wei Jiang; Xiang Liu; Jun Zhang; Chao Yu
Journal:  Int J Mol Med       Date:  2020-01-22       Impact factor: 4.101

7.  m6A modification promotes miR-133a repression during cardiac development and hypertrophy via IGF2BP2.

Authors:  Benheng Qian; Ping Wang; Donghong Zhang; Lianpin Wu
Journal:  Cell Death Discov       Date:  2021-06-26

8.  PKM1 Exerts Critical Roles in Cardiac Remodeling Under Pressure Overload in the Heart.

Authors:  Qinfeng Li; Chao Li; Abdallah Elnwasany; Gaurav Sharma; Yu A An; Guangyu Zhang; Waleed M Elhelaly; Jun Lin; Yingchao Gong; Guihao Chen; Meihui Wang; Shangang Zhao; Chongshan Dai; Charles D Smart; Juan Liu; Xiang Luo; Yingfeng Deng; Lin Tan; Shuang-Jie Lv; Shawn M Davidson; Jason W Locasale; Philip L Lorenzi; Craig R Malloy; Thomas G Gillette; Matthew G Vander Heiden; Philipp E Scherer; Luke I Szweda; Guosheng Fu; Zhao V Wang
Journal:  Circulation       Date:  2021-06-09       Impact factor: 39.918

Review 9.  Heart Plasticity in Response to Pressure- and Volume-Overload: A Review of Findings in Compensated and Decompensated Phenotypes.

Authors:  Fotios G Pitoulis; Cesare M Terracciano
Journal:  Front Physiol       Date:  2020-02-13       Impact factor: 4.566

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.